Targacept, Inc.

Catalyst Biosciences, Inc.

Attenua, Inc.

Matt S Melvin

Srinivasa Rao Akireddy

Yunde Xiao

Balwinder Singh Bhatti

Jason Daniel Speake

Daniel Yohannes

Ronald Joseph Heemstra

Craig Harrison Miller

Anatoly A Mazurov

Lan Miao

Scott R Breining

Philip S Hammond

Regina C Whitaker

Yun-De Xiao

Srinivasa V Murthy

Srinivisa Rao Akireddy

V Srinivasa Murthy

The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for use, and their pharmaceutical compositions.

Nicotinic receptor non-competitive antagonists

The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for use, and their pharmaceutical compositions.

Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteroaryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the &#x3b1;4&#x3b2;2 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle).

Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloalkanes

Sub-type selective amides of diazabicycloalkanes

Growing community of inventors

Winston-Salem, NC, United States of America

Matt S Melvin